After coronary bypass, desmopressin recipients with abnormal platelet function had no increased chest drainage versus desmopressin recipients with normal function.
In plain wordsAfter coronary bypass, desmopressin recipients with abnormal platelet function had no increased chest drainage versus recipients with normal function.
- Peptide
- Desmopressin
- Outcome
- No significant changeMediastinal chest tube drainage by platelet-function stratum
- Study
n: not reported in source
- Comparator
- Desmopressin-treated patients with normal platelet-fibrinogen function (group 1)
- Outcome group
- Bleeding and clotting · Cardiovascular
- Studied dose
- 0.3 microgram.kg-1As given in this study (human).
Source sentences
The desmopressin-treated patients in group 2 neither experienced increased mediastinal chest tube drainage nor received increased amounts of homologous blood products when compared to those in group 1.
2 context sentences(design, population, supporting numbers)
One hundred fifteen patients completed a prospective randomized double-blind, placebo-controlled trial designed to evaluate the effect of desmopressin acetate (0.3 microgram.kg-1)
Group 1 (TEG:MA greater than 50 mm) consisted of 86 patients, of whom 44 received desmopressin and 42 received placebo. Twenty-nine patients had abnormal platelet function (TEG:MA less than 50 mm) and were designated as group 2. In group 2, 13 received desmopressin and 16 placebo.